Leadership Team

Devdatt (Dev) Kurdikar serves as the Chairman, President and Chief Executive Officer of embecta. Previously, Dev was the President and CEO of Cardiac Science Corporation (CSC), a global leader in the manufacturing and marketing of automated external defibrillators (AEDs) for public access, education, police, and fire and rescue markets. CSC had been acquired by a private equity firm via bankruptcy proceedings, and under Dev’s leadership, CSC returned to profitable growth and was sold in a successful exit to ZOLL Medical.

Prior to that role, Dev was the Vice President and General Manager, Men’s Health, an important growth business within Urology and Pelvic Health at Boston Scientific Corp (NYSE: BSX). Dev was in the same role at American Medical Systems (AMS) and led the Men’s Health business through a significant business turnaround, and then the carve-out and sale to BSX, where Dev led the business through its integration into BSX. Before joining AMS, Dev served as Vice President, Marketing, Baxter International Inc. (NYSE: BAX), where he worked directly with the company’s top executives on a global commercial initiative to drive market access. Previously, he was the Vice President, Marketing for the Infusion Systems business for the U.S. region where he played a key role in stabilizing the business while under a consent decree, and launched a new wireless enabled infusion pump. In his 11 years with Baxter, Dev held leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations. He began his career as a Senior Research Engineer at The Monsanto Company.

Dev is currently a member of the Board of Directors of Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), AdvaMed (Advanced Medical Technology Association) and LMG Holdings (a portfolio company of The Riverside Company).

Dev holds a Bachelor in Chemical Engineering from the University of Bombay (India). He earned a Master of Science in Chemical Engineering from Washington State University (Washington), a Ph.D. in Chemical Engineering from Purdue University (Indiana), and a Master of Business Administration from Washington University (Missouri).

Jean Casner serves as SVP, Chief Human Resources Officer, and has over 30 years of global human resources strategy, design and operations experience across a range of industries. Most recently, she served as Senior Vice President and Chief Human Resources Officer for Renalytix, PLC, an emerging in-vitro diagnostic medical device company, where she was responsible for building the HR function in preparation for rapid growth following FDA approval of its groundbreaking diagnostic test, KidneyIntelX.dkd. Prior to Renalytix, Jean served as SVP and Chief Human Resources Officer of Cantel Medical Corp., a global medical products company focused on infection prevention products. There, she was responsible for the global human capital strategy, encompassing talent development, talent acquisition, succession planning, total rewards, benefits, diversity, equity and inclusion and HR operations. Previously, Jean also held HR leadership positions of increasing responsibility in the areas of HR Operations and Compensation and Benefits at the National Basketball Association (NBA), Merck & Co., The Dial Corporation (now Henkel), Johnson & Johnson, and ORC (now Mercer).

Jean holds a Bachelor of Arts degree in English from the University of Virginia.

Shaun Curtis serves as SVP, Global Manufacturing & Supply Chain. Shaun is responsible for leading global operations, consisting of 1,200 associates with plants located in Ireland, USA, and China. Accountability includes the performance of Safety, Quality, Delivery, Financials, Continuous Improvement and launching new products across the manufacturing network.

Previously, Shaun was the Manufacturing Director at BD Plymouth, UK (part of the Integrated Diagnostic Solutions Business), responsible for a plant manufacturing billions of Vacutainer tubes and blood collection needles a year. Shaun also represented Operations as part of the North-West European Leadership team where he worked with senior leaders developing growth strategies for the region.

Prior to joining BD, Shaun was the Engineering Manager at Cooper Standard Automotive, Plymouth, UK. The manufacturing Plant was a Tier 1 supplier of extruded weather seals to the car industry and supplied to companies including Ford, Rover, Honda, and GM. The role involved leading an engineering team responsible for all engineering activities in a plant of more than 600 associates. Before this, Shaun worked at Pall Filtration, UK.

Shaun holds a Master of Business Administration from Northampton University, UK. He earned an Honors Degree in Mechanical Engineering from Plymouth University. He also achieved a Higher National Diploma in Mechanical Engineering at Swindon College.

Jake Elguicze serves as as embecta’s Chief Financial Officer.  Previously Jake was with Teleflex, a $2.5 billion global provider of medical technologies, where he served as the company's Treasurer and Head of Investor Relations. Jake is a CPA and began his career in public accounting with PricewaterhouseCoopers before spending 8 years at Motorola in operating finance roles.

Jake joined Teleflex in 2006 to build out the financial planning and analysis function. He assumed responsibility for investor relations in 2009 and added the Treasurer role in 2011, where he transformed the capital structure to support the company’s new M&A strategy.

Jake earned a Bachelor of Science in Accounting from the University of Scranton in Scranton, PA, and a Master of Business Administration in Finance from St. Joseph’s University in Philadelphia, PA.

Jeff Mann serves as the General Counsel and Head of Business Development for embecta. Jeff brings 22 years of medical device and law firm experience to embecta, including leadership in M&A, securities, corporate governance, intellectual property, commercial transactions, compliance and litigation, and he has deep roots in the medical, pharmaceutical and biotechnology sectors.

Most recently, he served as General Counsel and Corporate Secretary of Cantel Medical Corp., a global medical products company focused on infection prevention products, where he was responsible for the global legal, compliance, and environmental health and safety teams. He also led several business development projects, including the eventual sale of Cantel to Steris plc for $4.6 billion. Simultaneously, he held a year-long assignment as global leader of Cantel’s R&D team, managing a team of 130 associates based in Germany, Italy, the United Kingdom and the U.S.

Prior to Cantel, he spent 14 years with Boston Scientific Corporation in roles of increasing responsibility, including M&A, venture capital investments, SEC and corporate governance patent strategy, litigation, and business unit support for the $3 billion MedSurg group. He also served on the Board of Directors of Preventice Solutions and as Chair of its Compensation Committee.

Jeff holds a Bachelor of Science in Civil and Environmental Engineering from Lafayette College in Easton, PA, and a J.D. from Boston College Law School, magna cum laude.

Nimish Muzumdar serves as SVP and President, North America and is responsible for leading the United States and Canada commercial teams and executing the region’s long-term growth strategy.  He has more than 25 years of experience in US retail pharmacy and hospital channels and a track record of driving growth in the highly competitive generic drugs industry. Most recently, he served as Senior Vice President & Head, Generics (Retail, Institutional, Hospitals & Clinics) at Sandoz, where he helped shape the organization’s commercial strategy, culture, and operational foundation for long-term success. Previously in his decade-plus at Sandoz, Nimish served as Director, Generics Oncology & Injectables; Executive Director, Generics Oncology & Injectables; Executive Director, Retail Generics; and Vice President & Head of Generics. Prior to Sandoz, he held marketing roles of increasing leadership responsibility for Ranbaxy USA, Watson Laboratories, and Dr. Reddy’s Laboratories.

Nimish holds a Bachelor of Science – Pharmacy from the University of Mumbai and an MBA from New York Institute of Technology.